Cantor Fitzgerald raises target for AbbVie stock to USD 290.00
Published on 10/08/2026 at 16:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 240.90 at Lang & Schwarz on October 8, 2026 at 4:02 p.m. CEST, down 1.21 percent versus the prior close of EUR 243.85. According to MarketBeat on October 8, 2026, Cantor Fitzgerald raised its AbbVie target from USD 285.00 to USD 290.00 and kept an overweight rating.
AbbVie events build the pipeline
On July 31, 2026, AbbVie reported second-quarter revenue of USD 16.99 billion, up 10.20 percent year over year, while adjusted earnings per share reached USD 3.65 versus a USD 3.61 consensus estimate, according to MarketBeat.
On September 30, 2026, AbbVie reported Phase 2 results for zumilokibart in atopic dermatitis, with 346 participants randomized across three doses and placebo, according to FinanzNachrichten.
What does the target change mean?
MarketBeat says Cantor Fitzgerald's USD 290.00 target implies 6.87 percent upside from the stock price used in its report. The valuation signal sits alongside a development risk: AbbVie said on October 7, 2026 that Temab-A remains investigational and has not been approved by global regulators, even after two FDA Breakthrough Therapy Designations, according to AbbVie.
Upcoming dates matter for AbbVie
AbbVie has an ex-dividend date of October 15, 2026, with a quarterly dividend of USD 1.73 per share, according to MarketBeat. The company is scheduled to report third-quarter 2026 results on October 30, 2026, according to Stock Analysis.
Stock trades below the prior close
AbbVie stock was trading at EUR 240.90 at Lang & Schwarz on October 8, 2026 at 4:02 p.m. CEST, down 1.21 percent from the EUR 243.85 prior close dated October 7, 2026. The finance data snapshot puts AbbVie's market capitalization at USD 474.7 billion and its 52-week range at USD 190.75 to USD 274.94 as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 4:02 p.m. CEST): EUR 240.90
- Change versus prior close: minus 1.21 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 243.85
- Market capitalization: USD 474.7 billion (as of October 8, 2026)
- 52-week range: USD 190.75-274.94 (as of October 8, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 30, 2026
Market context: Market report S&P 500.
